Subscribe

Spotlight -

Community/Retail|

Pharmacy Technician|

Brian A. Jonas, MD, PhD, FACP

Articles by Brian A. Jonas, MD, PhD, FACP

a vibrant microscopic view of malignant hematologic cells, their structure distorted and disorganized, while GFH009, represented by a glowing pathway | Image Caption: catalin | stock.adobe.com

Efficacy and Safety in CPX-351 vs 7+3 in Adults Younger Than 60 Years With AML-MRC or t-AML

ByVera Pervitsky, PharmD, BCOP, BCPS,Ila M. Saunders, PharmD, BCOP, DipACLM, FHOPA,Mimi Lo, PharmD, BCOP, BCPS,Rebecca Young, PharmD, BCOP,Benjamin Moskoff, PharmD, BCOP,Yunyi Ren, MS,Machelle Wilson, PhD,Brian A. Jonas, MD, PhD, FACP,Marisela Banez, PharmD, BCOP, BCPS,Julie Guglielmo, PharmD, BCOP

August 7th 2025

CPX-351 shows promise for younger adults with therapy-related AML, offering improved survival post-transplant despite lower initial remission rates.

Latest Updated Articles

Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights

ACIP Meeting: COVID-19 Vaccines to be Administered Through Shared Clinical Decision-Making

ACIP Meeting: Combined MMRV Vaccine, Hepatitis B Vaccine Restricted for Some Age Groups

Intelligent Pharmacy: Leveraging AI and Automation to Enhance Patient Care and Pharmacist Roles

FDA Approves Keytruda Qlex Subcutaneous Injection for Adult and Pediatric Patients With Solid Tumors

FDA Approves 1.5% Ruxolitinib Cream for Pediatric Atopic Dermatitis

© 2025 MJH Life Sciences^®

All rights reserved.